文献速递角膜与眼表疾病

干眼病的病理生理学:已知知识与未来研究方向

The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research.
PubMed 文献 · Ophthalmology · 2017-01-01

干眼是慢性炎症性疾病,由多种外源或内源因素引发泪膜不稳定和高渗。泪液成分改变导致炎症循环,引起眼表上皮病变和神经刺激。环孢素和利非斯特是美国FDA批准的两种疗法,抑制T细胞活化和细胞因子产生,但并非对所有患者有效。临床前研究已发现其他潜在治疗靶点、生物标志物和增强内源性免疫调节通路的策略。

要点

  • 干眼是慢性炎症性疾病,由外源或内源因素引发泪膜不稳定和高渗。
  • 急性干燥激活眼表上皮应激信号通路,触发先天炎症介质产生。
  • 环孢素和利非斯特抑制T细胞活化和细胞因子产生,但并非对所有患者有效。

核心结论

  • 干眼是慢性炎症性疾病,由多种外源或内源因素引发泪膜不稳定和高渗,形成炎症循环导致眼表上皮病变和神经刺激。

研究设计与样本

  • 综述,总结过去几十年临床和实验室研究发现的干眼病理生理机制及未来研究方向。

主要发现

  • 急性干燥激活眼表上皮和驻留免疫细胞的应激信号通路,触发先天炎症介质产生,刺激基质金属蛋白酶产生、炎症细胞募集和树突状细胞成熟。
  • 这些介质与自身抗原暴露结合,可导致适应性T细胞介导的反应。
  • 角膜屏障破坏由蛋白酶介导的上皮紧密连接溶解引起,导致细胞死亡加速、脱屑、角膜表面不规则且润滑不良、上皮伤害感受器暴露和敏化。
  • 结膜杯状细胞功能障碍和死亡由辅助性T细胞1细胞因子干扰素γ促进。

关键数值与推荐

  • 环孢素和利非斯特是2种美国FDA批准的疗法,抑制T细胞活化和细胞因子产生。
  • 这些疗法并非对所有患者的眼部不适和角膜上皮病变均有效。

临床怎么用

  • 环孢素和利非斯特是US FDA批准的干眼疗法,抑制T细胞活化和细胞因子产生,但并非对所有患者的眼部不适和角膜上皮病变均有效。

局限性

  • 环孢素和利非斯特并非对所有患者的眼部不适和角膜上皮病变均有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical and laboratory studies performed over the past few decades have discovered that dry eye is a chronic inflammatory disease that can be initiated by numerous extrinsic or intrinsic factors that promote an unstable and hyperosmolar tear film. These changes in tear composition, in some cases combined with systemic factors, lead to an inflammatory cycle that causes ocular surface epithelial disease and neural stimulation. Acute desiccation activates stress signaling pathways in the ocular surface epithelium and resident immune cells. This triggers production of innate inflammatory mediators that stimulate the production of matrix metalloprotease, inflammatory cell recruitment, and dendritic cell maturation. These mediators, combined with exposure of autoantigens, can lead to an adaptive T cell-mediated response. Cornea barrier disruption develops by protease-mediated lysis of epithelial tight junctions, leading to accelerated cell death; desquamation; an irregular, poorly lubricated cornea surface; and exposure and sensitization of epithelial nociceptors. Conjunctival goblet cell dysfunction and death are promoted by the T helper 1 cytokine interferon gamma. These epithelial changes further destabilize the tear film, amplify inflammation, and create a vicious cycle. Cyclosporine and lifitegrast, the 2 US Food and Drug Administration-approved therapies, inhibit T-cell activation and cytokine production. Although these therapies represent a major advance in dry eye therapy, they are not effective in improving discomfort and corneal epithelial disease in all patients. Preclinical studies have identified other potential therapeutic targets, biomarkers, and strategies to bolster endogenous immunoregulatory pathways. These discoveries will, it is hoped, lead to further advances in diagnostic classification and treatment.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Pflugfelder SC, de Paiva CS. The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research. Ophthalmology. 2017. PMID: 29055361. doi:10.1016/j.ophtha.2017.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。